Article
Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Neuro-oncology - 4 Nov 2019
Burgenske Danielle M, Yang Jie, Decker Paul A, Kollmeyer Thomas M, Kosel Matthew L, Mladek Ann C, Caron Alissa A, Vaubel Rachael A, Gupta Shiv K, Kitange Gaspar J, Sicotte Hugues, Youland Ryan S, Remonde Dioval, Voss Jesse S, Fritcher Emily G Barr, Kolsky Kathryn L, Ida Cristiane M, Meyer Fredric B, Lachance Daniel H, Parney Ian J, Kipp Benjamin R, Giannini Caterina, Sulman Erik P, Jenkins Robert B, Eckel-Passow Jeanette E, Sarkaria Jann N
Abstract excerpt
BACKGROUND: Glioblastoma (GBM) represents an aggressive cancer type with a median survival of only 14 months. With fewer than 5% of patients surviving 5 years, comprehensive profiling of these rare patients could elucidate prognostic biomarkers that may confer better patient outcomes. We utilized multiple molecular approaches to characterize the largest patient cohort of isocitrate dehydrogenase (IDH)-wildtype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
